Jounce Therapeutics to Participate in William Blair’s Biotech Focus Conference

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Dmitri Wiederschain, Ph.D., Chief Scientific Officer will participate in a panel discussion at the William Blair’s Biotech Focus Conference taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.

A webcast of the panel will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.

About Jounce TherapeuticsJounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a monotherapy and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce obtained IND clearance for and exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Investor and Media Contacts:

Mark YoreJounce Therapeutics, Inc.+1-857-200-1255 [email protected]

Julie SeidelStern Investor Relations+1-212-362-1200[email protected]

You May Also Be Interested In

• SOS Ltd. Announces Receipt of NYSE Non-compliance Letter Regarding Class A Ordinary Shares Trading Price
• Carahsoft Sponsors 17th Annual Billington Cybersecurity Summit in Washington, D.C. on September 8-10, 2026
• trivago N.V.: Dr. Mathias Hansen, Vesting of Restricted Share Units.